Hallux Announces Closing of $7.1 Million Series A Financing

LAGUNA HILLS, Calif.--()--Hallux Incorporated, an investigational-stage pharmaceutical company focused on developing a new dosage form and route of administration for treating onychomycosis, announced the completion of Series A financing of $7.1 million. Deerfield Management led the round.

The new capital will be deployed to advance Hallux's proprietary terbinafine micro-insert dosage form into phase 2A clinical trials, with the goal of demonstrating safety, efficacy, and tolerability in patients with distal lateral subungual onychomycosis.

"Onychomycosis remains a major market in the United States and abroad that is generally underserved by existing prescription treatment options," said Mark Taylor, Hallux Chief Executive Officer. "The oral therapies carry the risk of systemic side effects while the topical products are associated with underwhelming cure rates and yearlong dosing requirements. Our approach utilizes subungual drug administration that delivers high concentrations of terbinafine directly to the site of infection. In this way, we hope to improve efficacy and compliance with negligible systemic exposure." Taylor continued, "We are grateful to Deerfield for their confidence and support and look forward to working closely with their highly experienced healthcare investment and operating teams in bringing this exciting new product and therapy to market."

About Hallux

Hallux is developing an investigational micro-insert for subungual delivery and treatment of distal lateral subungual onychomycosis. The dosage form is biodegradable and delivers high concentrations of terbinafine hydrochloride directly and selectively to the site of infection over a period of time. Results from pilot studies are encouraging and suggest that the subungual treatment procedure is safe and well tolerated. Hallux is planning to further evaluate efficacy, safety, and tolerability in a series of single site clinical studies commencing in the first half of 2016.


Hallux, Inc.
Mark Taylor, 949-637-4656
[email protected]


Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.